RxDoctor Payments Data

Sue Chung, MD

Rheumatology · Porter Ranch, CANPI 1033396767

Payments from drug & device makers

$361,698in general payments, 2019–2025

Across 83 payments — averaging $4357.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$148K
  • Eli Lilly$126K
  • GSK$50K
  • Sanofi US Services Inc.$36K
  • Biogen$2K
  • AbbVie$127
  • plus $355 from 5 others

What the payments were for

  • Travel & lodging$1,27854%
  • Food & beverage$1,08346%

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis14$147,877
Eli Lilly8$125,730
GSK18$50,091
Sanofi US Services Inc.11$35,758
Biogen14$1,759
AbbVie3$127
Shockwave Medical, Inc1$126
Sobi, Inc4$82
Pfizer6$74
Amgen2$46
Boston Scientific2$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$361,698 in reported general payments places this provider in the 90th percentile of 808 rheumatology providers in California.

See all rheumatology providers in California

Medicare billing

Part B allowed, 2024
$34,515
Medicare patients
111
Services billed
937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab60$516,614
Cosentyx Sensoready PenSecukinumab46$480,178
Humira PenAdalimumab55$440,824
Enbrel SureclickEtanercept24$223,766
Taltz AutoinjectorIxekizumab15$207,902
Humira(Cf)Adalimumab17$110,593
KevzaraSarilumab18$81,898
ActemraTocilizumab16$37,414
Celecoxib70$12,174
Mycophenolate Mofetil70$10,720
Hydroxychloroquine Sulfate139$7,135
MethotrexateMethotrexate Sodium159$4,728
Cevimeline Hcl15$4,348
Leflunomide40$3,935
Gabapentin108$2,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf)$127$110,59317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 808 rheumatology providers in California.

Other rheumatology in Porter Ranch

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →